US judge: FTC did not conduct improper probe in Watson/Apotex case, and Bisaro should testify
This article was originally published in Scrip
Executive Summary
A federal magistrate judge has determined that, in reviewing the facts provided to the court in the unusual fight between Watson's CEO Paul Bisaro and the US Federal Trade Commission, Watson has not proven its allegations that the FTC overstepped its authority and committed misconduct during its probe of a patent settlement between the generic drug maker and Cephalon. The commission is suing Cephalon on antitrust grounds, claiming reverse payment settlements with generic drug makers on the firm's sleep disorder drug Provigil (modafinil) were illegal and delay generic competition until 2012.